A Phase 3 interventional study of Elafibranor and Placebo in Nonalcoholic Steatohepatitis (NASH) With Fibrosis, sponsored by Genfit. Terminated at 326 sites in 25 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-03-23.
Sponsored by Genfit · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 5th largest by enrollment of the 460 interventional ones that give a count, is one of 28 that started in 2016, is one of 29 in phase 3, and was the 171st registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 28 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,157 is above the median of 60 across 1,177 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
Genfit is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
Genfit has 4 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females participating in this study must be of nonchildbearing potential or using highly efficient for the full duration of the study and for 1 month after the end of treatment, as described below:
For participants with type 2 diabetes, glycemia must be controlled. If glycemia is controlled by antidiabetic drugs, change in anti-diabetic therapy must follow these requirements:
Initiation of any other antidiabetic drugs is allowed after Randomization based on treating physicians' judgment, except for glitazones which are prohibited 6 months prior to diagnostic liver biopsy until the end of treatment.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Coated tablets dosed at 120mg Elafibranor; oral administration; one tablet per day before breakfast with a glass of water
Drug: Elafibranor
Coated placebo tablets; oral administration; one tablet per day before breakfast with a glass of water
Drug: Placebo
Also known as: GFT505
Number of Elafibranor-treated Participants Relative to Placebo Achieving Resolution of Nonalcoholic Steatohepatitis Without Worsening of Fibrosis
To evaluate the effect of Elafibranor compared to placebo on liver histology in nonalcoholic steatohepatitis (NASH) participants with fibrosis by assessing the following endpoint: The number of Elafibranor-treated participants relative to placebo achieving NASH resolution without worsening of fibrosis. This outcome measure is for the surrogate endpoint analysis.
Time frame: Measurement at 72 weeks
Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes
Composite long-term outcome measured by the number of participants with the onset of any of the adjudicated events, composed of death due to any cause, histological liver cirrhosis, and the full list of portal hypertension/cirrhosis related events as follows: liver transplantation; model for end stage liver disease (MELD) score greater than or equal to 15 for participants with baseline score less than or equal to 12, and onset of variceal bleeding requiring hospitalization, hepatic encephalopathy with West Haven/Conn score greater than or equal to 2 and requiring hospitalization, spontaneous bacterial peritonitis, and ascites requiring treatment. The MELD scale ranges from 6 to 40, showing how much a participant needs a liver transplant: higher number is more urgent. The West Haven/Conn scale is 5-point (0 to 4) grading severity of hepatic encephalopathy: higher score means worse hepatic encephalopathy. This outcome measure is for the long-term endpoint analysis.
Time frame: From first randomization up to early termination of the study corresponding to 54 months (54 months being the longest duration for any given participant)
Number of Elafibranor-treated Participants Relative to Placebo Achieving Improvement of Fibrosis of at Least 1 Stage
To evaluate the effect of Elafibranor compared to placebo on liver histology in nonalcoholic steatohepatitis (NASH) participants by assessing the following endpoint: The number of Elafibranor-treated participants relative to placebo achieving improvement of liver fibrosis of at least 1 stage according to NASH Clinical Research Network (CRN) Scoring. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.
Time frame: Measurements at 72 weeks
Change From Baseline of Hemoglobin A1c (HbA1c) in Diabetic Participants After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo
Hemoglobin A1c (HbA1c) were tested at Week 72. Changes from baseline in HbA1c at Week 72 were evaluated. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.
Time frame: Measurements after 72 weeks of treatment and up to study termination
Change From Baseline of High-density Lipoprotein (HDL) Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo
High-density lipoprotein (HDL) cholesterol was tested at Week 72. Changes from baseline in HDL cholesterol were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.
Time frame: Measurements after 72 weeks of treatment and up to study termination
Change From Baseline of Low-density Lipoprotein (LDL) Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo
Low-density lipoprotein (LDL) cholesterol was tested at Week 72. Changes from baseline in LDL cholesterol were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.
Time frame: Measurements after 72 weeks of treatment and up to study termination
Change From Baseline of Homeostatic Model Assessment-IR (HOMA-IR) After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo in Non-diabetic Participants
Homeostatic model assessment-IR (HOMA-IR) was tested at Week 72. Changes from baseline in HOMA-IR were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.
Time frame: Measurements after 72 weeks of treatment and up to study termination
Change From Baseline of Non-high Density Lipoprotein Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo
Non-high density lipoprotein (HDL) cholesterol was tested at Week 72. Changes from baseline in non-HDL cholesterol were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.
Time frame: Measurements after 72 weeks of treatment and up to study termination
Change From Baseline of Triglycerides After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo
Triglycerides was tested at Week 72. Changes from baseline in triglycerides were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.
Time frame: Measurements after 72 weeks of treatment and up to study termination
The version 3 protocol for Brazil is included in the uploaded documents as it was part of the pre-specified plan, but this country was not used as part of the study.
| Milestone | 120 mg Elafibranor | Placebo |
|---|---|---|
| Started | 1437 | 720 |
| Full intent-to-treat population | 1437 | 720 |
| Full safety population | 1433 | 717 |
| Completed | 0 | 0 |
| Not completed | 1437 | 720 |
| Withdrew: Randomized and not treated (due to non-compliance with protocol) | 4 | 3 |
| Withdrew: Administrative reasons by sponsor | 1251 | 616 |
| Withdrew: Death | 4 | 3 |
| Withdrew: Endpoint event | 52 | 24 |
| Withdrew: Lost to follow-up | 22 | 11 |
| Withdrew: Protocol violation | 15 | 15 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Withdrawal by subject | 85 | 45 |
| Withdrew: Investigator decision | 1 | 1 |
| Withdrew: Follow-up not possible | 1 | 2 |
To evaluate the effect of Elafibranor compared to placebo on liver histology in nonalcoholic steatohepatitis (NASH) participants with fibrosis by assessing the following endpoint: The number of Elafibranor-treated participants relative to placebo achieving NASH resolution without worsening of fibrosis. This outcome measure is for the surrogate endpoint analysis.
| Participants | 120 mg Elafibranor | Placebo |
|---|---|---|
| Number of Elafibranor-treated Participants Relative to Placebo Achieving Resolution of Nonalcoholic Steatohepatitis Without Worsening of Fibrosis | 138 | 52 |
Composite long-term outcome measured by the number of participants with the onset of any of the adjudicated events, composed of death due to any cause, histological liver cirrhosis, and the full list of portal hypertension/cirrhosis related events as follows: liver transplantation; model for end stage liver disease (MELD) score greater than or equal to 15 for participants with baseline score less than or equal to 12, and onset of variceal bleeding requiring hospitalization, hepatic encephalopathy with West Haven/Conn score greater than or equal to 2 and requiring hospitalization, spontaneous bacterial peritonitis, and ascites requiring treatment. The MELD scale ranges from 6 to 40, showing how much a participant needs a liver transplant: higher number is more urgent. The West Haven/Conn scale is 5-point (0 to 4) grading severity of hepatic encephalopathy: higher score means worse hepatic encephalopathy. This outcome measure is for the long-term endpoint analysis.
| Participants | 120 mg Elafibranor | Placebo |
|---|---|---|
| Baseline — Events | 0 | 0 |
| Baseline — Censored | 0 | 0 |
| Baseline — No events or not censored | 1437 | 720 |
| 6 months — Events | 1 | 1 |
| 6 months — Censored | 48 | 26 |
| 6 months — No events or not censored | 1388 | 693 |
| 12 months — Events | 1 | 1 |
| 12 months — Censored | 159 | 82 |
| 12 months — No events or not censored | 1277 | 637 |
| 18 months — Events | 53 | 28 |
| 18 months — Censored | 374 | 195 |
| 18 months — No events or not censored | 1010 | 497 |
| 24 months — Events | 56 | 31 |
| 24 months — Censored | 609 | 301 |
| 24 months — No events or not censored | 772 | 388 |
| 30 months — Events | 57 | 31 |
| 30 months — Censored | 778 | 393 |
| 30 months — No events or not censored | 602 | 296 |
| 36 months — Events | 60 | 32 |
| 36 months — Censored | 1049 | 531 |
| 36 months — No events or not censored | 328 | 157 |
| 42 months — Events | 61 | 32 |
| 42 months — Censored | 1293 | 652 |
| 42 months — No events or not censored | 83 | 36 |
| 48 months — Events | 61 | 32 |
| 48 months — Censored | 1374 | 687 |
| 48 months — No events or not censored | 2 | 1 |
| 54 months — Events | 61 | 32 |
| 54 months — Censored | 1376 | 688 |
| 54 months — No events or not censored | 0 | 0 |
To evaluate the effect of Elafibranor compared to placebo on liver histology in nonalcoholic steatohepatitis (NASH) participants by assessing the following endpoint: The number of Elafibranor-treated participants relative to placebo achieving improvement of liver fibrosis of at least 1 stage according to NASH Clinical Research Network (CRN) Scoring. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.
| Participants | 120 mg Elafibranor | Placebo |
|---|---|---|
| Number of Elafibranor-treated Participants Relative to Placebo Achieving Improvement of Fibrosis of at Least 1 Stage | 176 | 79 |
Hemoglobin A1c (HbA1c) were tested at Week 72. Changes from baseline in HbA1c at Week 72 were evaluated. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.
| mmol/L | 120 mg Elafibranor | Placebo |
|---|---|---|
| Change From Baseline of Hemoglobin A1c (HbA1c) in Diabetic Participants After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo | 0.03 (-0.19 to 0.25) | -0.01 (-0.24 to 0.23) |
High-density lipoprotein (HDL) cholesterol was tested at Week 72. Changes from baseline in HDL cholesterol were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.
| mmol/L | 120 mg Elafibranor | Placebo |
|---|---|---|
| Change From Baseline of High-density Lipoprotein (HDL) Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo | -0.036 (-0.050 to -0.021) | -0.052 (-0.073 to -0.032) |
Low-density lipoprotein (LDL) cholesterol was tested at Week 72. Changes from baseline in LDL cholesterol were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.
| mmol/L | 120 mg Elafibranor | Placebo |
|---|---|---|
| Change From Baseline of Low-density Lipoprotein (LDL) Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo | -0.250 (-0.295 to -0.204) | -0.217 (-0.282 to -0.151) |
Homeostatic model assessment-IR (HOMA-IR) was tested at Week 72. Changes from baseline in HOMA-IR were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.
| index | 120 mg Elafibranor | Placebo |
|---|---|---|
| Change From Baseline of Homeostatic Model Assessment-IR (HOMA-IR) After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo in Non-diabetic Participants | -0.789 (-2.979 to 1.402) | -0.930 (-3.347 to 1.486) |
Non-high density lipoprotein (HDL) cholesterol was tested at Week 72. Changes from baseline in non-HDL cholesterol were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.
| mmol/L | 120 mg Elafibranor | Placebo |
|---|---|---|
| Change From Baseline of Non-high Density Lipoprotein Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo | -0.445 (-0.499 to -0.392) | -0.271 (-0.348 to -0.195) |
Triglycerides was tested at Week 72. Changes from baseline in triglycerides were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.
| mmol/L | 120 mg Elafibranor | Placebo |
|---|---|---|
| Change From Baseline of Triglycerides After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo | -0.466 (-0.537 to -0.395) | -0.148 (-0.249 to -0.046) |
Collected over Adverse event information was collected at every study visit from screening up to early termination of the study corresponding to 54 months (54 months being the longest duration for any given participant) plus 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 120 mg Elafibranor | 6/1,437 (0.4%) | 190/1,433 (13.3%) | 1,227/1,433 (85.6%) |
| Placebo | 3/720 (0.4%) | 95/717 (13.2%) | 601/717 (83.8%) |
| Event | 120 mg Elafibranor | Placebo |
|---|---|---|
| Atrial fibrillationCardiac disorders | 2/1433 | 5/717 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/1433 | 5/717 |
| PneumoniaInfections and infestations | 6/1433 | 3/717 |
| DiarrhoeaGastrointestinal disorders | 2/1433 | 3/717 |
| Abdominal painGastrointestinal disorders | 1/1433 | 3/717 |
| Urinary tract infectionInfections and infestations | 2/1433 | 3/717 |
| SyncopeNervous system disorders | 2/1433 | 3/717 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/1433 | 3/717 |
| Acute myocardial infarctionCardiac disorders | 5/1433 | 0/717 |
| Non-cardiac chest painGeneral disorders | 5/1433 | 2/717 |
| Event | 120 mg Elafibranor | Placebo |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 160/1433 | 81/717 |
| Urinary tract infectionInfections and infestations | 145/1433 | 77/717 |
| DiarrhoeaGastrointestinal disorders | 148/1433 | 68/717 |
| NauseaGastrointestinal disorders | 140/1433 | 50/717 |
| NasopharyngitisInfections and infestations | 134/1433 | 52/717 |
| Back painMusculoskeletal and connective tissue disorders | 120/1433 | 60/717 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 102/1433 | 58/717 |
| InfluenzaInfections and infestations | 115/1433 | 54/717 |
| Upper respiratory tract infectionInfections and infestations | 107/1433 | 46/717 |
| FatigueGeneral disorders | 103/1433 | 49/717 |
| Age, Continuous(years) | 120 mg Elafibranor | Placebo | Total |
|---|---|---|---|
| Mean | 54.0 ± 11.78 | 54.4 ± 11.63 | 54.1 ± 11.73 |
| Sex: Female, Male(Participants) | 120 mg Elafibranor | Placebo | Total |
|---|---|---|---|
| Female | 622 | 308 | 930 |
| Male | 815 | 412 | 1227 |
| Ethnicity (NIH/OMB)(Participants) | 120 mg Elafibranor | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 336 | 177 | 513 |
| Not Hispanic or Latino | 1089 | 532 | 1621 |
| Unknown or Not Reported | 12 | 11 | 23 |
| Race (NIH/OMB)(Participants) | 120 mg Elafibranor | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 8 | 1 | 9 |
| Asian | 53 | 27 | 80 |
| Native Hawaiian or Other Pacific Islander | 3 | 3 | 6 |
| Black or African American | 28 | 10 | 38 |
| White | 1234 | 614 | 1848 |
| More than one race | 93 | 49 | 142 |
| Unknown or Not Reported | 18 | 16 | 34 |
| Weight(kg) | 120 mg Elafibranor | Placebo | Total |
|---|---|---|---|
| Mean | 98.0 ± 21.90 | 96.3 ± 20.84 | 97.4 ± 21.56 |
| Height(cm) | 120 mg Elafibranor | Placebo | Total |
|---|---|---|---|
| Mean | 169.1 ± 10.48 | 168.8 ± 10.23 | 169.0 ± 10.39 |
| BMI(kg/m^2) | 120 mg Elafibranor | Placebo | Total |
|---|---|---|---|
| Mean | 34.1 ± 6.13 | 33.6 ± 5.77 | 33.9 ± 6.01 |
| Waist Circumference(cm) | 120 mg Elafibranor | Placebo | Total |
|---|---|---|---|
| Mean | 111.9 ± 14.19 | 110.4 ± 13.48 | 111.4 ± 13.97 |
6 further baseline measures are reported on the registry.
Showing the first 100 of 326 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
The record gives a start of Mar 2016, a primary completion of Oct 2020 and a completion of Oct 2020. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2022, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elifibranor
Non-alcoholic Fatty Liver Disease →